Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Predictive value of early brain atrophy on response in patients treated with interferon β.
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Change in the clinical development program for laquinimod
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.

Pages